# Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

> **NCT00378703** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 361 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Sorafenib Tosylate
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00378703
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-14
- **Primary completion:** 2014-02-07
- **Final completion:** 2017-03-21
- **Target enrollment:** 361 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378703, "Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00378703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*